Setmelanotide powder

Product Introduction:

Product Name: Setmelanotide powder

Product Source: Synthetic

Assay Specification: ≥98%

CAS Number: 920014-72-8

Testing Method: HPLC

Active Ingredient: Setmelanotide

Chemical Formula: C₁₅₈H₂₅₄N₄₆O₄₅S₇

Molecular Weight: 3647.02 g/mol

Product Appearance: White to off-white lyophilized powder.

Product Application: Pharmaceutical and research use

Storage Conditions: Refrigerate at 2°C–8°C, protect from light and moisture

Shelf Life: 24 months

Products  Description  

Xi'an Tihealth High-Quality Setmelanotide Powder

Xi'an Tihealth Biotechnology Co., Ltd. offers high-quality, high-specification, high-content Setmelanotide Powder (Setmelanotide Powder) with a core focus on high purity (≥98%) and pharmaceutical-grade quality. Produced in strict compliance with the United States Pharmacopeia (USP)/European Pharmacopoeia (EP) and GMP standards, it is indicated for the treatment of hereditary obesity caused by POMC/LEPR gene mutations. The product undergoes multidimensional testing including HPLC and mass spectrometry to ensure stable composition and controlled impurities. It appears as a white lyophilized powder that dissolves into a clear solution, meeting requirements for injectable formulations. Leveraging solid-phase synthesis technology and a comprehensive quality control system, it demonstrates excellent batch consistency and 24-month storage stability at 2-8°C. Having passed multiple technical validations, it provides compliant and reliable raw material support for medical institutions, research, and pharmaceutical clients.

Products Function

Setmelanotide functions as a selective MC4R agonist, restoring impaired signaling in patients with POMC/LEPR-related obesity. It addresses the root cause of excessive hunger and weight gain by modulating appetite and energy expenditure pathways.

Mechanism of Action

The drug binds to and activates the MC4R in the hypothalamus, a key regulator of energy balance. In patients with POMC or LEPR mutations (which disrupt endogenous MC4R signaling), Setmelanotide bypasses the genetic defect to normalize appetite suppression and metabolic regulation.

Products Application

<!--[if !supportLists]-->· <!--[endif]-->Approved Use: Treatment of POMC deficiency or LEPR deficiency obesity (rare genetic disorders).

<!--[if !supportLists]-->· <!--[endif]-->Research Potential: Exploration in obesity-related comorbidities (e.g., diabetes, cardiovascular risk) and other MC4R-related metabolic conditions.

<!--[if !supportLists]-->· <!--[endif]-->Pharmaceutical Development: As a raw material for injectable formulations in clinical and preclinical studies.

Pharmacological effects

<!--[if !supportLists]-->1. <!--[endif]-->Central Effects: Reduces hunger, increases satiety, and decreases caloric intake.

<!--[if !supportLists]-->2. <!--[endif]-->Metabolic Effects: Enhances energy expenditure and improves body composition (reduces fat mass).

<!--[if !supportLists]-->3. <!--[endif]-->Long-Term Outcomes: Clinical trials show sustained weight loss (10–30% of baseline) over 52 weeks in target patient populations. 

Toxicological Effects

Common Adverse Events: Mild to moderate injection-site reactions, hyperpigmentation (due to melanocortin receptor activation), and transient increases in blood pressure.

Safety Profile: Generally well-tolerated in clinical trials; no significant organ toxicity reported.

Contraindications: Not recommended for patients with functional MC4R pathways (normal signaling) due to potential overactivation risks.